Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of rotigotine transdermal patch on early morning motor impairment and sleep disorders in idiopathic Parkinson's disease
2004-002598-21Phase 3Completed
- Sponsor
- Schwarz Pharma
- Start
- Nov 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rotigotine in Parkinson's disease (PD), sponsored by Schwarz Pharma. Primary endpoint: Motor performance (early morning motor impairment). Started Nov 2004; status: completed.
02
Drugs
rotigotine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2004-002598-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002598-21.